Shattuck Labs (STTK) EBIT Margin (2019 - 2025)
Shattuck Labs (STTK) posted quarterly EBIT Margin of 1071.6% for Q3 2025, down 47367.0% year-over-year from N/an in Q3 2024, and down 79.22% quarter-over-quarter from 597.93% in Q3 2024.
Powered by 
Analysis
Shattuck Labs (STTK) EBIT Margin (2019 - 2025) Analysis & Trends
Shattuck Labs (STTK) has reported EBIT Margin for 7 consecutive years, with 1071.6% the latest figure, recorded in Q3 2025.
- In Q3 2025, EBIT Margin fell 47367.0% year-over-year to 1071.6%; the TTM figure through Mar 2026 stood at 5266.4% (down 364000.0% YoY), while the FY2025 annual figure was 5150.8%, down 374253.0% from the prior year.
- EBIT Margin fell to 1071.6% in Q3 2025 per STTK's latest filing, from 597.93% in the prior quarter.
- Across five years, EBIT Margin topped out at 30.87% in Q4 2021 and bottomed at 55316.0% in Q2 2022.
- Historically, EBIT Margin has averaged 9137.83% across 5 years, with a median of 1797.67% in 2024.
- Annual changes were most pronounced in 2022 — EBIT Margin plunged 5473666 bps — and 2023, when it surged 4394250 bps.
- Shattuck Labs' EBIT Margin stood at 30.87% in 2021, then sank by 21929 bps to 6737.44% in 2022, then soared by 61 bps to 2654.2% in 2023, then surged by 77 bps to 597.93% in 2024, then tumbled by 79 bps to 1071.6% in 2025.
- Business Quant data shows STTK's EBIT Margin at 1071.6% in Q3 2025, 597.93% in Q3 2024, and 1427.1% in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Shattuck Labs | 885.09 Mn | 885.09 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -1,071.60% |
| Sep 30, 2024 | -597.93% |
| Jun 30, 2024 | -1,427.10% |
| Mar 31, 2024 | -1,797.67% |
| Dec 31, 2023 | -2,654.20% |
| Sep 30, 2023 | -4,168.80% |
| Jun 30, 2023 | -11,373.50% |
| Mar 31, 2023 | -38,001.75% |
| Dec 31, 2022 | -6,737.44% |
| Sep 30, 2022 | -11,900.47% |
| Jun 30, 2022 | -55,316.00% |
| Dec 31, 2021 | 30.87% |
| Sep 30, 2021 | -925.26% |
| Jun 30, 2021 | -579.34% |
| Mar 31, 2021 | -547.27% |
| Dec 31, 2020 | -895.01% |
| Sep 30, 2020 | -486.20% |
| Jun 30, 2020 | -198.68% |
| Mar 31, 2020 | -227.18% |
| Dec 31, 2019 | -270.26% |